Novel small-molecule inhibitors of the vascular endothelial growth factor receptor

Alex A. Adjei

doi:10.3816/CLC.2007.s.005

Novel small-molecule inhibitors of the vascular endothelial growth factor receptor

Alex A. Adjei

Medical Oncology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Sustained angiogenesis is one of the hallmarks of carcinogenesis. Vascular endothelial growth factor (VEGF) is a critical molecule mediating pro-angiogenic signals against which a number of therapeutic approaches have been designed. The 2 predominant approaches to inhibiting VEGF signaling are the use of monoclonal antibodies to block the receptor or ligand, and small-molecule receptor kinase inhibitors. There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review.

Original language	English (US)
Pages (from-to)	S74-S78
Journal	Clinical lung cancer
Volume	8
Issue number	SUPPL. 2
DOIs	https://doi.org/10.3816/CLC.2007.s.005
State	Published - Feb 2007

Keywords

AMG-706
Axitinib
Cediranib
Kinase inhibitors
Pazopanib
XL647

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.3816/CLC.2007.s.005

Cite this

@article{a6c55467522f41269c12df51bb49956c,

title = "Novel small-molecule inhibitors of the vascular endothelial growth factor receptor",

abstract = "Sustained angiogenesis is one of the hallmarks of carcinogenesis. Vascular endothelial growth factor (VEGF) is a critical molecule mediating pro-angiogenic signals against which a number of therapeutic approaches have been designed. The 2 predominant approaches to inhibiting VEGF signaling are the use of monoclonal antibodies to block the receptor or ligand, and small-molecule receptor kinase inhibitors. There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review.",

keywords = "AMG-706, Axitinib, Cediranib, Kinase inhibitors, Pazopanib, XL647",

author = "Adjei, {Alex A.}",

note = "Funding Information: Dr Adjei has received research support from AstraZeneca, Bayer/Onyx, Pfizer, Novartis Oncology, Lilly Oncology, Exelixix, and sanofi-aventis. This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of Axitinib; AZD2171 (cediranib) as a single agent and in combination with chemotherapy; pazopanib; AMG-706; and XL647 in advanced solid malignancies.",

year = "2007",

month = feb,

doi = "10.3816/CLC.2007.s.005",

language = "English (US)",

volume = "8",

pages = "S74--S78",

journal = "Clinical lung cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Novel small-molecule inhibitors of the vascular endothelial growth factor receptor

AU - Adjei, Alex A.

N1 - Funding Information: Dr Adjei has received research support from AstraZeneca, Bayer/Onyx, Pfizer, Novartis Oncology, Lilly Oncology, Exelixix, and sanofi-aventis. This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of Axitinib; AZD2171 (cediranib) as a single agent and in combination with chemotherapy; pazopanib; AMG-706; and XL647 in advanced solid malignancies.

PY - 2007/2

Y1 - 2007/2

N2 - Sustained angiogenesis is one of the hallmarks of carcinogenesis. Vascular endothelial growth factor (VEGF) is a critical molecule mediating pro-angiogenic signals against which a number of therapeutic approaches have been designed. The 2 predominant approaches to inhibiting VEGF signaling are the use of monoclonal antibodies to block the receptor or ligand, and small-molecule receptor kinase inhibitors. There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review.

AB - Sustained angiogenesis is one of the hallmarks of carcinogenesis. Vascular endothelial growth factor (VEGF) is a critical molecule mediating pro-angiogenic signals against which a number of therapeutic approaches have been designed. The 2 predominant approaches to inhibiting VEGF signaling are the use of monoclonal antibodies to block the receptor or ligand, and small-molecule receptor kinase inhibitors. There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review.

KW - AMG-706

KW - Axitinib

KW - Cediranib

KW - Kinase inhibitors

KW - Pazopanib

KW - XL647

UR - http://www.scopus.com/inward/record.url?scp=34147186711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147186711&partnerID=8YFLogxK

U2 - 10.3816/CLC.2007.s.005

DO - 10.3816/CLC.2007.s.005

M3 - Article

C2 - 17382028

AN - SCOPUS:34147186711

SN - 1525-7304

VL - 8

SP - S74-S78

JO - Clinical lung cancer

JF - Clinical lung cancer

IS - SUPPL. 2

ER -

Novel small-molecule inhibitors of the vascular endothelial growth factor receptor

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this